Artikel
In human GBM myeloid cells contribute to tumor vascularization by homing to the perivascular niche and overexpression of proangiogenic factors
Suche in Medline nach
Autoren
Veröffentlicht: | 25. August 2015 |
---|
Gliederung
Text
Glioblastoma multiforme (GBM), one of the most malignant brain tumors, is characterized by high proliferation rates, strong vascularization and accumulation of microglia/macrophages. The function and phenotype of these immune cells within glioma tissue is highly discussed.
We aimed to analyze the contribution of microglia/macrophages on different grades of astrocytomas. Here, we investigated their activation status and expression of proangiogenic factors, as well as their interaction with the vasculature.
During surgical treatment, tissue samples of 65 patients with astrocytomas (WHO°III and °IV) or epilepsy (control) were obtained. These tissues were either used for immunofluorescence staining or enzymatically homogenization. Prepared cell suspensions were analyzed by FACS concerning activation markers of microglia/macrophages. In addition, CD11b+ cells were isolated by MACS technology and qRT-PCRs regarding proangiogenic factors were performed.
We found altered phenotypes of microglia/macrophages within the different grades of astrocytoma accompanied by remodeling of the tumor vasculature. Tissue of GBM patients showed larger vessel calibers and a high association of microglia/macrophages with tumor blood vessels compared to astrocytomas WHO°III and controls. Additionally, we observed different fractions of myeloid cells by FACS, identifying microglia/macrophages and granulocytes dependent on the grade of malignancy. Here, we established subgroups of GBM patients based on percentage of the granulocyte fraction. The GBM group with high amounts of granulocytes contained microglia/macrophages with upregulated activation markers (CD86, MHCI, MHCII) and also higher expression of CD45 in comparison to controls or WHO°III. Furthermore we detected increased levels of various proangiogenic factors (e.g. VEGF, CXCL8, CXCL2, CD13) in GBM samples.
Our data demonstrate, that cells of the myeloid lineage are able to support vascularization in human GBM. Their proangiogenic potential is defined by localization in the perivascular niche and expression of angiogenic factors. Thus, myeloid cells contribute to tumor progression. Regarding the still insufficient treatment options for GBM patients, myeloid cells may represent an additional therapeutic target to improve the survival.